CompletedPHASE1, PHASE2NCT01861730

Phase 1/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants

Studying Tuberculosis

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Aeras
Principal Investigator: Ann Ginsberg, MD, PhD
Aeras
Intervention: AERAS-404(biological)
Enrollment: 243 enrolled
Eligibility: All sexes
Timeline: 2013 – 2017

Study locations (4)

PHRU, Chris Hani Baragwanath Hospital, Johannesburg, Guateng, South Africa
Shandukani Research, Johannesburg, Hillbrow, South Africa
KID-CRU, Tygerberg Hospital, Cape Town, Tygerberg, South Africa
South African TB Vaccine Initiative (SATVI), Worcester, South Africa

Collaborators

Statens Serum Institut · Sanofi Pasteur, a Sanofi Company · National Institute of Allergy and Infectious Diseases (NIAID) · International Maternal Pediatric Adolescent AIDS Clinical Trials Group

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT01861730 on ClinicalTrials.gov

Other trials for Tuberculosis

Additional recruiting or active studies for the same condition.

See all trials for Tuberculosis →

← Back to all trials